Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing pantoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (*H. pylori*).
## Primary Indications
Treatment of *H. pylori* infection in patients with active peptic ulcer disease or a history of peptic ulcer disease.
## Adult Dosing
The typical regimen is one capsule (containing pantoprazole 40 mg, amoxicillin 500 mg, and clarithromycin 500 mg) taken twice daily for 10 to 14 days.
* **Alternative Regimen:** If local resistance rates for clarithromycin are high (>20%), a bismuth-based quadruple therapy may be preferred.
## Pediatric Dosing
Dosing in pediatric patients is not well-established and should be determined by a specialist.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically required for pantoprazole, amoxicillin, or clarithromycin with mild to moderate renal impairment. Severe renal impairment may require dose adjustment for amoxicillin and clarithromycin. Consult prescribing information for specific recommendations.
* **Hepatic Impairment:** Pantoprazole dose may need to be reduced in severe hepatic impairment. Consult prescribing information.
## Contraindications
* Known hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or other macrolides.
* History of severe immediate hypersensitivity reaction to penicillin or other beta-lactam antibiotics.
* Concomitant use with rifampin or rifabutin.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, abdominal pain, headache, and dysgeusia. Clostridioides difficile-associated diarrhea (CDAD) can occur. Rash, urticaria, and allergic reactions are possible with amoxicillin.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Clarithromycin is a potent CYP3A4 inhibitor and can increase levels of drugs metabolized by this enzyme (e.g., warfarin, certain statins, benzodiazepines).
* **Proton Pump Inhibitors (PPIs):** Pantoprazole can decrease the absorption of drugs that require acidic gastric pH (e.g., ketoconazole, itraconazole, certain antiretrovirals).
* **Warfarin:** Increased INR and bleeding risk.
* **Digoxin:** Increased digoxin levels.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Assess for diarrhea and abdominal cramping, and rule out CDAD.
* Monitor INR in patients taking warfarin.
* Ensure successful eradication of *H. pylori* via a validated non-invasive test (e.g., stool antigen test, urea breath test) after completion of therapy.
## Clinical Pearls
* Administer the full course of therapy as prescribed, even if symptoms improve.
* Instruct patients to take pantoprazole before meals to optimize acid suppression.
* Ensure adequate hydration.
* If a patient develops a rash, discontinue amoxicillin and consider alternative antibiotic therapy.
**Disclaimer:** This information is intended for clinical use and does not replace the manufacturer's official prescribing information. Always consult the current product monograph and patient-specific factors before prescribing.
